Dolutegravir

Published November 04, 2012; Updated September 12, 2014
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-03
Selected Reference
8. Curtis LD, Min S, Nichols G, et al; SPRING-2 and SINGLE Teams. Once-daily dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART) naive adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467). In: Program and abstracts of the 7th International Antiviral Society Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur. Abstract TUPE282.